

Cohort Study D₃ Injection Dose 100000 IU Transdermal They Have Suffered with Warts

Mohanad L. AL-Jawhar¹, Shala Hussien Hano¹, Ban Abbas Nasir¹, Nameer AL-Soudany²

Ibn Sina University for Medical and Pharmaceutical Sciences/Faculty of Dentistry/Basic Sciences,
Baghdad-Iraq¹

Ibn Sina University of Medical and Pharmaceutical Sciences/College of Medicine/Department of
Dermatology, Baghdad-Iraq²



ABSTRACT— Skin warts is the most common viral skin infection, Effective vitamin D₃ has been utilized to treat skin warts nowadays, in the past many other methods were used to treat warts like electrocautery, cryotherapy, or laser ablation. Intralesional substance D₃ infusion is now used in the management of all type of this disease. Forty-five patients were treated with vitamin D₃ injection (males and females), all got an intralesional infusion of 0.2 mL of nutrient of this 100,000 IU into the foundation of mother affected lesion for two meetings and first month and fourth months after the methodology. The level of the reaction was characterized as complete, fractional, and no response. To assess the viability and security of intralesional (IL) nutrient D₃ 100,000 IU was infused in the treatment of skin warts. A total of 45 patients who complain of skin warts and accept to participate in this study who attended the dermatology department of both genders were included in this study, aged between 20-45 years old randomly selected. This study showed that the efficacy of vitamin D₃ in the treatment of skin warts was 86.6 %. The new treatment of skin warts using vitamin D₃ 100,000 IU injection is more effective than the traditional warts treatment.

KEYWORDS: vitamin D₃, skin warts, intralesional, infection and treatment

1. INTRODUCTION

Warts are a benign epidermal proliferation (infections of the skin) which is brought by the human papillomavirus (HPV). There are more than 100 kinds of HPV that are answerable for a wide range of sorts of the skin virus, which incorporate normal warts, plantar warts, flat warts, and genital warts [1], [2]. It simultaneously replicates with the separation of keratinocytes, prompting the development of disease into tiny parts in the granular cell layer. The disease pieces are delivered at one moment with the shedding of the verruca, leading to disrupt of the viral materials to other regions of the skin [5]. The usual method of warts treatment is with destructive methods like electrocautery, cryotherapy, or laser ablation of the external layer. Topical vitamin D₃ has been used to treat warts with variable success rates, one of these by intralesional vitamin D₃ injection which is a more effective method than other routes of D₃ in the treatment of common warts [3], [4], [6]. Intralesional immunotherapy has become more normally utilized for the treatment of warts. The immediate infusion of antibodies or parasitic antigens into warts is accepted to invigorate the host cell-intervened resistance and dispense with the tainted cells [8]. High-resolution rates were shown in many studies 45.5-72.9% of patients who received intralesional vitamin D₃ injection achieved complete resolution and that 60.9-88.6% achieved more than 50% improvement, studies showed that vitamin D₃ dose was not associated with the treatment response in patients with all types of warts. Only mild effects were noticed regarding adverse effects, such as local pain, swelling, and erythematic symptoms [7]. Intralesional vitamin D₃ injection is an effective and safe method used for warts treatment option. In fourteen studies with vitamin D₃ injection to the patients who complain of skin warts, a wide range of warts

were incorporated, intralesional nutrient D₃ infusion was fundamentally more compelling than the fake treatment (complete reaction: OR, 3.027; 95% certainty stretch [9]. Viral warts are a common infection with plenty of treatment choices that have variable achievement rates. The warts are headstrong to treatment with frustrating reactions and high repeat rates. This disease is significant because it might prompt the improvement of specific skin tumors, specifically, squamous cell carcinoma [10]. Of late, treatment with intralesional vitamin D₃ infusions has been acquired because of its viability in clearing moles by animating the phone-intervened immunity [11]. Factors that increment the gamble of the disease include Wounds to the skin, Skin contaminations that break the skin surface, now and again getting the hands wet, hands or feet that sweat vigorously (hyperhidrosis), swimming out in the open pools, nail gnawing, direct contact with others', moles, scratching or shaving your warts, which can spread the contamination to a different region of your body.

Effect of nutrition in warts treatment:

- A. Eliminate thought food allergens, like dairy (milk, cheddar, and frozen yogurt), wheat (gluten), soy, and corn. B
- B. Eat food sources high in B-vitamin and calcium, like almonds, beans, and entire grains.
- C. Eat antioxidant-rich foods, including fruits and vegetables.
- D. Try to avoid refined food.
- E. Decease red meats and lean meats.
- F. Use healthy cooking oils, such as olive oil.
- G. Reduce trans fatty acids, found in commercially baked goods, such as cookies, crackers, cakes, and French fries.
- H. Reduce caffeine, alcohol, sugar, and exercise, 5 days a week [14- 16].

Effect of Herbs:

Green tea: For antioxidant effects. Use caffeine-free products.

Reishi mushroom: For antiviral and immunity activity.

Olive leaf: For antiviral and immune activity. Topical applications may also be effective for

Treating warts:

Banana peel patch: Cut a piece of banana peel and place it over the wart.

Raw garlic patch [17], [18].

Mechanism of action of vitamin D₃:

Vitamin D, when applied topically, controls epidermal cell multiplication and is engaged with the arrangement of antimicrobial peptides. We begin to involve nutrient D₃ to show its activity as an insusceptible - remedial particle and its effective impacts [19]. Vitamin D₃ could animate cytokine discharge by upregulating vitamin D receptor and hydroxylase gene [20], [21]. Some detailed and expanded serum interferon-gamma levels after intralesional nutrient D₃ injection [22]. Vitamin D; is a gathering of fat-solvent ketosteroids answerable to upgrade gastrointestinal assimilation of Ca, Mg, and PO₄, and has numerous many natural impacts. All people, a significant mixture found in the gathering are vitamin D₃. A fundamental safe reaction is stayed away from. Moreover, a modest quantity of disease proteins is communicated in the basal and the stratum spinosum, they can be probably going to be perceived by pancreas cells and invading lymphocytes [29], [30]. However, the resilience of patients to these treatment modalities is poor, since they regularly cause torment, particularly in kids, related with scarring and continuous repeat, and once in a while scarring or pigmentation after treatment [31]. In recent years, wart treatments include intralesional injections of tuberculin purified protein derivative (PPD); measles, mumps,

and rubella (MMR) vaccine; Mycobacterium vaccine; Ksharodaka (an alkaline aqueous solution of Apamarga Kshara); and Candida albicans antigen. It is thought that the host immune system is activated to recognize the virus, leading to wart clearance [32], [33]. This treatment approach is known as intralesional immunotherapy.

Treatment of skin warts:

1- TX. S.A, $C_5H_8O_2$, CH_2O , Occlusion, Topical 5-fluorouracil, Caustics, Retinoic acid, Vitamin D analogs [23]

2- TX: Cryotherapy, Laser, Hyperthermia, Surgery, Photodynamic therapy [24].

3-TX Podocon-25 and (PPT), $C_{14}H_{16}N_4$, local immune treatment put the treatment under the lesion area, (INF), H_2 block receptor, Zn, oral retinoids, local affected area cytotoxic chemotherapy, Psychological, Cidofovir [25], [26].

3. Mechanism of action:

3.1 The steps of the activity for nutrient D_3 peer

The epidermis has a chemical structure for nutrient D_3 analogs are keratinocytes, pancreas cells, cells that produce darkening pigment in the skin, cells that produce the collagen, and endothelial cell [34]. So

A. It deals with nutrient D chemical structure (VDR) can control cell development, separation with invulnerable capacity. The restrains and multiplication of keratinocytes with tweaks epidermal separation

B. Supplement D forestall creation in a few star incendiary cytokines by White blood cell clones, including IL-2 and IFN- γ .

C. The restrains IL-6 (from B cell) and IL-8 (which was created by WBC).

D. The restrains record of granulocyte-WBC province animating element with courier ribonucleic corrosive.

E. E. It stops the movement of CTL. Also Normal Executioner cells [35]. leads to the induction of antimicrobial peptide expression [31]. Some studies suggest that it has an immune-modulatory effect.

Methodology:

Study design: It is a cohort study design with an analytic component. Study place: The information took from DR Ali and lazim dermatologist private. Clinic Study population: 45 people 27 males and 18 females (20-50) years old participated in the study. Sample size: The sample size (N) for this study will be 45 patients whose has skin warts, 27 males, and 18 females who accept to participate in the study.

Selection criteria:

Inclusion criteria:

A. Forty-five patients, males (25) and females (20) with single or multiple warts attend the clinic; the age group included in the study was (20-50) years.

B. Patients with no concurrent systemic or topical treatment for warts

C. Exclusion criteria: It involved immuno-suppressed patients, pregnant ladies, breastfeeding ladies, and people on different medical modalities of disease in past about fourteen days of infusion. Patient with a history of touchiness to nutrients. D_3 .

Ethical permission: Permission to conduct the study had been taken from A written consent from patients to perform the study was obtained before the data collection stage started.

Data collection and management:

Forty –five patients who complain of skin warts (males and females) who attend the dermatology

department of the hospitals were randomly selected, they were classified by age and gender into groups, were injected with vitamin D₃ 100,000 IU solution was slowly injected into the base of each wart by using an insulin syringe, vitamin D₃ ampules 100,000 IU/ml were used. We give a slow gentle intralesional injection of substance D₃ with no local anesthesia after appropriate encouragement with reassurance for patients. The injections were repeated 2 weeks apart, follow-up depending on lesion size was obtained by picturing the lesion site before starting the treatment, and follow-up was obtained after 2 months after last injection. Data were divided into groups according to age (below 34 and above 34 years, the cut-off point was the age mean, and according to gender (male and female). Data were managed by SSPS and chi-square test was used.

4. Result

4.1 Demographic distribution of the patients

The study showed that the sample consisted of males and females (males were twenty-seven patients, females were 18 patients) all were accepted to participate in the study, males about 60% and females about 40% out of the total. This result is shown in Figure 1. The study showed that the age of the patients was between 20-45 years, thirty-one (68.8%) of patients were below 34 years and fourteen (31.2%) were above 34 years (the cut-off point of age was the mean which is 34 years. This is found in Figure 1. Figure 2 shows that out of a total of 45 patients, 34 patients had a primary response (during follow up after 2 months), 26 of them (76.5%) were below 34 years old and 8 (23.5%) were above 34 years old, while 5 (45.5%) below 34 years and 6 (54.5%) above 34 years show no response. That means the primary response was significantly higher in patients with age below 34 years old a, so the efficacy of vitamin D₃ intralesional injection shows a higher response in the young age group.




Figure 1: Demographic distribution (gender)




Figure 2: primary effect of vit D3 injection according to age

The result in Figure 3 shows that out of total of 45 patients 33 patients show primary response, 23 male (69.7%) had a primary response (during follow-up after 2 months), while 10 females (30.3%) had primary responsibility. Of the patients with no response, 4 males (33.3%) and 8 females (66.7%) had no response. That means, the vitamin D₃ intralesional injection shows high efficacy in males than in females according to the primary response. The result in Figure 4 was about the response after 4 months of vitamin D₃ intralesional injection and it was out of total of 45 patients, 37 patients had a response (during follow up after 4 months), 28 of them (75.7%) were below 34 years old and 9 (24.3%) above 34 years old, while 3

(37.5%) below 34 years and 5 (62.5%) above 34 years show no response. That means the response after 4 months of vitamin D₃ intralesional injection of the warts was significantly higher in patients with age below 34 years old. The result in Figure 5 shows that out of total of 45 patients 39 patients show a response after 4 months of injection, 26 male (66.7%) had a response (during follow-up after 4 months), while 13 females (33.3%) had a response. Of the patients with no response, 1 male (16.7%) and 5 females (83.3%) had no response. That means, the Vitamin D₃ intralesional injection shows high efficacy in males than in females according to response after 4 months.




Figure 3: primary effect of vitamin D₃ injection according to gender




Figure 4: Four months effect of vitamin D₃ injection according to age

Gender Affected (4 month)




Figure 5: Four months effect of vitamin D₃ injection according to gender

In Table 1, the result shows that out of 45 patients who complain of skin warts, 33 (73.7%) of them show a response after 2 months of injection, and 39 (86.6%) patients show a response after 4 months (males and females)

Table 1 vitamin D3 effects according to the duration of injection

Variable	Response after 2 months		Response after 4 months	
	No.	%	No.	%
Male	23	69.7	26	66.7
Female	10	30.3	13	33.3
Total	33	100	39	100
≤ 43years	26	76.5	28	75.7
≥ 43years	8	23.5	9	24.3
Total	34	100	37	100

5. Discussion

Warts are small, rough, hard growths that are similar in color to the rest of the skin [36], [37]. A range of types of wart has been identified, varying in shape and site affected, as well as the type of human papillomavirus involveds [38], [39]. This study shows that, the total response rate was 86.6% (66.7% of males respond to treatment and 33.3% of females were respond), this high figure of response was similar to that found in turkey [40], and also this result was similar to that found in India [41]. In this study, the response after 4 months of follow up is higher than the response after 2 months of follow up, which means the response to vitamin D₃ injection increase with duration and the number of injections. This was similar to the study of [42], in which the response rate was high after 6 months. The result was inconsistent with [43] study which show a lower rate of response which might be because of fewer quantities of infusion with a long span between every meeting. [44] there were 3 gatherings of patients bunch 1 treated with intralesional 2% zinc sulfate, bunch 2 with intralesional 2% vitamin D₃ and bunch 3 intralesional ordinary saline for 4 times meetings every 40 days, thus the total reaction rate with vitamin D₃ in this study was 62.9%, and this rate is somewhat like our study. In this study, the result shows that the response rate was higher in males than in females and this result was inconsistent with a study in Tikrit and [45] in which There was no critical connection between clinical reaction and either age, sex, this differences may be due to sampling and cultural causes. The high response level in this study was similar to the study in India which shows also a high response level of [46]. In Egypt, there is a similar study that shows the same result about vitamin D₃ injection in the treatment of skin warts with a clearance rate (45%), this difference in the percentage is due to the sampling [47]. In another study, the result was a complete clearance in 73.3%, halfway freedom in 20%, and no improvement in 6.7% (2) of patients [48]. A fake treatment controlled concentrate by Abdel [49], showed disappearance of warts in 56.25% (18 out of 32) of patients with intralesional supplement D₃ in cutaneous warts. Be that as it may, our review showed a superior reaction. Another fake treatment-controlled concentrate by [50] utilized 0.2 ml intralesional vitamin D once a month for two meetings for normal warts. It showed total clearance in 45% of the patients. Our review introduced better outcomes, presumably due higher dose.

6. Conclusions

Our review shows a helpful job of intralesional of the supplement D₃ in the treatment of skin warts. It is a basic, safe, financially savvy treatment methodology with a low repeat rate. Bigger case-control concentrates as well as in-vitro/in-vivo investigations are expected to clarify the specific system of activity of supplement D₃ in warts, and a larger sample group is needed in the future.

7. REFERENCES

[1] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon (FR): International Agency for Research on Cancer; 2007. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 90.) 1, Human Papillomavirus (HPV) Infection. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK321770/>

- [2] InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Warts: Overview. [Updated 2019 Nov 7]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279586/>
- [3] Chow, L. T., & Broker, T. R. (2013). Human papillomavirus infections: warts or cancer?. Cold Spring Harbor perspectives in biology, 5(7), a012997. <https://doi.org/10.1101/cshperspect.a012997>
- [4] Howley P. M., Lowy D. R. Papillomaviruses. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2299–354. (السنة خطأ وهي 2007)
- [5] Khanna N., (2016), “Illustrated Synopsis of Dermatology and Sexually Transmitted Diseases”, 5th ed. Delhi/ India: Elsevier.
- [6] Salman, S., Ahmed, M. S., Ibrahim, A. M., Mattar, O. M., El-Shirbiny, H., Sarsik, S., Afifi, A. M., Anis, R. M., Yakoub Agha, N. A., & Abushouk, A. I. (2019). Intralesional immunotherapy for the treatment of warts: A network meta-analysis. Journal of the American Academy of Dermatology, 80(4), 922–930.e4. <https://doi.org/10.1016/j.jaad.2018.07.003>
- [7] AlGhamdi, K. M., & Khurram, H. (2011). Successful treatment of periungual warts with diluted bleomycin using translesional multipuncture technique: a pilot prospective study. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 37(4), 486–492. <https://doi.org/10.1111/j.1524-4725.2011.01932.x>
- [8] Thappa, D. M., & Chiramel, M. J. (2016). Evolving role of immunotherapy in the treatment of refractory warts. Indian dermatology online journal, 7(5), 364–370. <https://doi.org/10.4103/2229-5178.190487>
- [9] Akl, E. M., Sorour, N. E., Abdou, A. G., & Elesawy, F. M. (2021). Does involucrin have a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study. Indian journal of dermatology, 66(5), 465–471. https://doi.org/10.4103/ijd.ijd_808_20
- [10] In Transplantation C. R. (2022). Retracted: Successful Treatment of Refractory Wart with a Topical Activated Vitamin D in a Renal Transplant Recipient. Case reports in transplantation, 2022, 9838495. <https://doi.org/10.1155/2022/9838495>
- [11] Raghukumar, S., Ravikumar, B. C., Vinay, K. N., Suresh, M. R., Aggarwal, A., & Yashovardhana, D. P. (2017). Intralesional Vitamin D3 Injection in the Treatment of Recalcitrant Warts: A Novel Proposition. Journal of cutaneous medicine and surgery, 21(4), 320–324. <https://doi.org/10.1177/1203475417704180>
- [13] Sorour, N. E., Elesawy, F. M., Abdou, A. G., Abdelazeem, S. E., & Akl, E. M. (2022). Intralesional injection of vitamin D in verruca vulgaris increases cathelicidin (LL37) expression; therapeutic and immunohistochemical study. The Journal of dermatological treatment, 33(1), 291–296. <https://doi.org/10.1080/09546634.2020.1750554>
- [14] Cvetnić, Z., & Vladimir-Knezević, S. (2004). Antimicrobial activity of grapefruit seed and pulp ethanolic extract. Acta pharmaceutica (Zagreb, Croatia), 54(3), 243–250.

- [15] Hegggers, J. P., Cottingham, J., Gusman, J., Reagor, L., McCoy, L., Carino, E., Cox, R., & Zhao, J. G. (2002). The effectiveness of processed grapefruit-seed extract as an antibacterial agent: II. Mechanism of action and in vitro toxicity. *Journal of alternative and complementary medicine (New York, N.Y.)*, 8(3), 333–340. <https://doi.org/10.1089/10755530260128023>
- [16] Lichtenstein, A. H., & Russell, R. M. (2005). Essential nutrients: food or supplements? Where should the emphasis be?. *JAMA*, 294(3), 351–358. <https://doi.org/10.1001/jama.294.3.351>
- [17] Cabrera, C., Artacho, R., & Giménez, R. (2006). Beneficial effects of green tea--a review. *Journal of the American College of Nutrition*, 25(2), 79–99. <https://doi.org/10.1080/07315724.2006.10719518>
- [18] Das, M., Sur, P., Gomes, A., Vedasiromoni, J. R., & Ganguly, D. K. (2002). Inhibition of tumour growth and inflammation by consumption of tea. *Phytotherapy research : PTR*, 16 Suppl 1, S40–S44. <https://doi.org/10.1002/ptr.797>
- [19] Raghukumar, S., Ravikumar, B. C., Vinay, K. N., Suresh, M. R., Aggarwal, A., & Yashovardhana, D. P. (2017). Intralesional Vitamin D3 Injection in the Treatment of Recalcitrant Warts: A Novel Proposition. *Journal of cutaneous medicine and surgery*, 21(4), 320–324. <https://doi.org/10.1177/1203475417704180>
- [20] Liu, P. T., Stenger, S., Li, H., Wenzel, L., Tan, B. H., Krutzik, S. R., Ochoa, M. T., Schaubert, J., Wu, K., Meinken, C., Kamen, D. L., Wagner, M., Bals, R., Steinmeyer, A., Zügel, U., Gallo, R. L., Eisenberg, D., Hewison, M., Hollis, B. W., Adams, J. S., ... Modlin, R. L. (2006). Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science (New York, N.Y.)*, 311(5768), 1770–1773. <https://doi.org/10.1126/science.1123933>
- [21] Osborne, J. E., & Hutchinson, P. E. (2002). Vitamin D and systemic cancer: is this relevant to malignant melanoma? *The British journal of dermatology*, 147(2), 197–213. <https://doi.org/10.1046/j.1365-2133.2002.04960.x>
- [22] Abou-Taleb, D., Abou-Taleb, H. A., El-Badawy, O., Ahmed, A. O., Thabiet Hassan, A. E., & Awad, S. M. (2019). Intralesional vitamin D3 versus intralesional purified protein derivative in treatment of multiple warts: A comparative clinical and immunological study. *Dermatologic therapy*, 32(5), e13034. <https://doi.org/10.1111/dth.13034>
- [23] Thomas, K. S., Keogh-Brown, M. R., Chalmers, J. R., Fordham, R. J., Holland, R. C., Armstrong, S. J., Bachmann, M. O., Howe, A. H., Rodgers, S., Avery, A. J., Harvey, I., & Williams, H. C. (2006). Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. *Health technology assessment (Winchester, England)*, 10(25), iii–87. <https://doi.org/10.3310/hta10250>
- [24] Kaçar, N., Taşlı, L., Korkmaz, S., Ergin, S., & Erdoğan, B. Ş. (2012). Cantharidin-podophylotoxin-salicylic acid versus cryotherapy in the treatment of plantar warts: a randomized prospective study. *Journal of the European Academy of Dermatology and Venereology : JEADV*, 26(7), 889–893. <https://doi.org/10.1111/j.1468-3083.2011.04186.x>
- [25] Gibbs, S., Harvey, I., Sterling, J., & Stark, R. (2002). Local treatments for cutaneous warts: systematic review. *BMJ (Clinical research ed.)*, 325(7362), 461.

- [26] Tan, O. T., Hurwitz, R. M., & Stafford, T. J. (1993). Pulsed dye laser treatment of recalcitrant verrucae: a preliminary report. *Lasers in surgery and medicine*, 13(1), 127–137. <https://doi.org/10.1002/lsm.1900130120>
- [27] Potlapati, A., Gangaiah, N., & George N. M. (2020). A study on safety and efficacy of intralesional vitamin D3 in cutaneous warts. *International Journal of Research in Dermatology*, 6(5) ,648-651. <http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20203749>
- [28] Shahriari, M., Kerr, P. E., Slade, K., & Grant-Kels, J. E. (2010). Vitamin D and the skin. *Clinics in dermatology*, 28(6), 663–668. <https://doi.org/10.1016/j.clindermatol.2010.03.030>
- [29] 13.Savant SS, Shah RA, Gore D. Electrosurgery. (2005). *Textbook and Atlas of Dermatosurgery and Cosmetology*. Published by ASCAD (Association of Scientific Cosmetologists and Dermatologists, Bombay). pp: 305-314.
- [30] Nasser N. (2012). Treatment of common warts with the immune stimulant Propionium bacterium parvum. *Anais brasileiros de dermatologia*, 87(4), 585–589. <https://doi.org/10.1590/s0365-05962012000400011>
- [31] Sterling, J. C., Handfield-Jones, S., Hudson, P. M., & British Association of Dermatologists (2001). Guidelines for the management of cutaneous warts. *The British journal of dermatology*, 144(1), 4–11. <https://doi.org/10.1046/j.1365-2133.2001.04066.x>
- [32] Shaheen, M. A., Salem, S. A., Fouad, D. A., & El-Fatah, A. A. (2015). Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. *Dermatologic therapy*, 28(4), 194–200. <https://doi.org/10.1111/dth.12230>
- [33] Singh, S., Chouhan, K., & Gupta, S. (2014). Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. *Indian journal of dermatology, venereology and leprology*, 80(6), 509–514. <https://doi.org/10.4103/0378-6323.144145>
- [34] Yamaguchi, Y., & Hearing, V. J. (2014). Melanocytes and their diseases. *Cold Spring Harbor perspectives in medicine*, 4(5), a017046. <https://doi.org/10.1101/cshperspect.a017046>
- [35] Nadkarni, N., Patil, S., Godse, K., (2013). *DYP Survival Guide for Postgraduate Dermatology Examination Part-II*. 2nd ed. India: Torrent Pharmaceuticals.
- [36] Loo, S. K., & Tang, W. Y. (2014). Warts (non-genital). *BMJ clinical evidence*, 2014, 1710.
- [37] “Warts: Overview”. U.S. National Library of Medicine. 30 July 2014. Archived from the original on 10 September 2017. <https://www.ncbi.nlm.nih.gov/books/NBK279586/>
- [38] Anderson, Keith; Keith, Jeff; Novak, Patricia D.; Elliot, Michelle A. (2005). *Mosby's Medical, Nursing & Allied Health Dictionary*. 5th ed. C.V. Mosby. ISBN 978-0-323-03736-5. Archived from the original on 7 January 2017.
- [39] "MedlinePlus: Warts". (2010). Archived from the original on 16 May 2013.

- [40] Nofal, A., Nofal, E., Yosef, A., & Nofal, H. (2015). Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. *International journal of dermatology*, 54(6), 667–671. <https://doi.org/10.1111/ijd.12480>
- [41] Sinha, S., Relhan, V., & Garg, V. K. (2015). Immunomodulators in warts: Unexplored or ineffective?. *Indian journal of dermatology*, 60(2), 118–129. <https://doi.org/10.4103/0019-5154.152502>
- [42] Kavya, M., Shashikumar, B. M., Harish, M. R., & Shweta, B. P. (2017). Safety and Efficacy of Intralesional Vitamin D3 in Cutaneous Warts: An Open Uncontrolled Trial. *Journal of cutaneous and aesthetic surgery*, 10(2), 90–94. https://doi.org/10.4103/JCAS.JCAS_82_16
- [43] Kareem, I., Ibrahim, I. M., Mohammed, S., & Ahmed, A. A. (2019). Effectiveness of intralesional vitamin D3 injection in the treatment of common warts: Single-blinded placebo-controlled study. *Dermatologic therapy*, 32(3), e12882. <https://doi.org/10.1111/dth.12882>
- [44] El Sayed, M. H., Sayed, F. S., & Afify, A. A. (2020). Intralesional zinc sulfate 2% vs intralesional vitamin D in plantar warts: A clinicodermoscopic study. *Dermatologic therapy*, 33(3), e13308. <https://doi.org/10.1111/dth.13308>
- [45] Shaldoum, D. R., Hassan, G., El Maadawy, E. H., & El-Maghraby, G. M. (2020). Comparative clinical study of the efficacy of intralesional MMR vaccine vs intralesional vitamin D injection in treatment of warts. *Journal of cosmetic dermatology*, 19(8), 2033–2040. <https://doi.org/10.1111/jocd.13272>
- [46] Gupta, S., Malhotra, A. K., Verma, K. K., & Sharma, V. K. (2008). Intralesional immunotherapy with killed Mycobacterium w vaccine for the treatment of ano-genital warts: an open label pilot study. *Journal of the European Academy of Dermatology and Venereology : JEADV*, 22(9), 1089–1093. <https://doi.org/10.1111/j.1468-3083.2008.02719.x>
- [47] Abdelaal, M. A., Abdelaziz, H. M., Ahmed, K. A., & Elsaie, M. L. (2021). Comparative Study of Intralesional Vitamin D3 Injection and Candida Albicans Antigen in Treating Plantar Warts. *Journal of drugs in dermatology : JDD*, 20(5), 546–549. <https://doi.org/10.36849/JDD.5264>
- [48] Moscarelli, L., Annunziata, F., Mjeshtri, A., Paudice, N., Tsalouchos, A., Zanazzi, M., & Bertoni, E. (2011). Successful treatment of refractory wart with a topical activated vitamin d in a renal transplant recipient. *Case reports in transplantation*, 2011, 368623. (Retraction published Case Rep Transplant. 2022 Feb 23;2022:9838495). <https://doi.org/10.1155/2011/368623>
- [49] Abdel-Azim, E. S., Abdel-Aziz, R., Ragale, M. H., & Mohamed, E. A. (2020). Clinical and dermoscopic evaluation of intralesional vitamin D3 in treatment of cutaneous warts: A placebo-controlled study. *Journal of Egypt Women's Dermatology Society*. 17(1):6-12. https://doi.org/10.4103/JEWD.JEWD_38_19
- [50] Kareem, I., Ibrahim, I. M., Mohammed, S., & Ahmed, A. A. (2019). Effectiveness of intralesional vitamin D3 injection in the treatment of common warts: Single-blinded placebo-controlled study. *Dermatologic therapy*, 32(3), e12882. <https://doi.org/10.1111/dth.12882>



This work is licensed under a Creative Commons Attribution Non-Commercial 4.0 International License.